5 More Top Growth Stocks

Are you really a growth investor?

It's worth asking. Fast-moving tech stocks have taken a beating recently, leading to a slew of bargains for those with the guts to buy. Just ask investors who hold shares of Blue Nile (Nasdaq: NILE  ) , which yesterday fell more than 7% when high-cost rival Zale (NYSE: ZLC  ) reported lousy results. Sheesh.

No matter. All-star investors bet on growth over the very long term. They know that:

  1. Businesses that make investors billions always begin as growth stocks.
  2. The best of them feature massive and identifiable competitive advantages.
  3. Growth as a strategy has the capacity to deliver 20% or greater annual returns for decades at a time.

How we do it
Of course, not all growth stocks will do. Our weekly hunt is for the next great multibagger. But unlike David Gardner and his team at Rule Breakers, who scour everything from financial statements to trade magazines to clinical reports in their research, we're going to rely on our Motley Fool CAPS investor-intelligence database.

Specifically, we're looking for stocks that have earned a five-star rating in CAPS and which are expected to grow their earnings by at least 20% annually over the next five years. Five-star stocks are those that the community, on the whole, believes will outperform the S&P 500.

Let's have the list
Now, with that preamble behind us, here are five more top growth stocks:

Company

No. of CAPS Ratings

Percent Bulls

5-Year Growth Estimate

Omrix Biopharmaceuticals (Nasdaq: OMRI  )

394

95.4%

22.9%

Compania de Minas Buenaventura (NYSE: BVN  )

724

97.7%

30.1%

Cresud (Nasdaq: CRESY  )

451

96.7%

38.1%

Catalyst Health

285

97.5%

20.1%

SandRidge Energy (NYSE: SD  )

448

97.3%

20%

Sources: Motley Fool CAPS, Yahoo! Finance.

Bear in mind that this isn't a list of recommendations. Instead, I offer these stocks as candidates for further research.

We've got some interesting companies to work with. Insiders have gone wild over SandRidge Energy. Pharmacy benefits administrator Catalyst Health is on the upswing. Johnson & Johnson (NYSE: JNJ  ) just spent $438 million to acquire Omrix. And metals miner Compania de Minas Buenaventura has been on Wall Street's buy list.

Cruddy, beautiful Cresud
My favorite today, though, is Global Gains recommendation Cresud, an Argentine food producer that has been badly hurt by a government plan to take over private pension plans.

If that sounds like a problem, it is, for all the reasons Bill Mann laid out here. The good news? Cresud's underlying business is buttressed by an excellent balance sheet. Executives have taken advantage by repurchasing shares almost daily. And with good reason, as CAPS investor MJKpayday pointed out in this pitch from December:

"Cresud's value comes from two areas: farm land (leasing and development) and food production and they do both very well. Just to put things in perspective: They've got about 1M acres of land , much of it farmland and there market cap is about 432M so that's about $432 an acre. In Iowa Farm land goes for about $4,000 an acre. And on top of that they have the food production business...Looks like a good deal and worth some further investigation for a real money pick."

Today, shares of Cresud are trading at roughly the value of the cash on its books. Let me click on my megaphone here: Attention, stock shoppers ... Sale in the global growth aisle.

But that's my take. I'm more interested to know what you think. Would you buy shares of Cresud at current prices? Let us know by signing up for CAPS today. It's 100% free to participate.

See you back here next week with five more top growth stocks. Fool on!

Fool contributor Tim Beyers is slowly nursing his CAPS rating back to health. He didn't own shares in any of the stocks mentioned in this article at the time of publication.

Tim seeks the best of  tech as a contributor to Motley Fool Rule Breakers, which counts Blue Nile and Omrix among its recommendations. Cresud is a Global Gains pick. Johnson & Johnson is an Income Investor recommendation. Get access to all of Tim's writings here. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 783901, ~/Articles/ArticleHandler.aspx, 10/21/2014 1:21:02 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement